AkesoGenX Corp.’s strategic vision is to bring to market significant new nano-diagnostic and nano-therapeutic medical products. The primary goal is to move the Kanzius RF field treatment forward to treat patients with highly lethal and resistant forms of cancer.
AkesoGenX Corp. has offices in Colorado and is headquartered in Houston, Texas in order to leverage deep and long-term relationships with the Baylor College of Medicine, the University of Texas MD Anderson Cancer Center, Rice University and Texas A&M University. In addition, the many medical institutions in the Texas Medical Center where the science of nanotechnology and of medical nano-therapeutics is underway in significant scale will be of great benefit to our future development.
AkesoGenX Corp. formed around the novel ideas and inventions of John Kanzius, the brilliant research of Dr. Steven Curley and the advanced nanomaterial’s industry expertise of Robert Zavala. The AkesoGenX management team envisions taking John Kanzius’s patented Noninvasive Radio Wave Cancer Treatment from pre-FDA research through to commercialization in concert with our strategic partners. The true goal is making this state-of-the-art technology available to those afflicted with Cancer.
The founding members of AkesoGenX Corp. originate from diverse yet complementary sectors within the medical, science and technology industries and bring years of experience and management expertise. The AkesoGenX management team will provide a solid foundation for the human clinical trials needed for commercialization of this innovative cancer treatment technology.